JP2006501207A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006501207A5 JP2006501207A5 JP2004525343A JP2004525343A JP2006501207A5 JP 2006501207 A5 JP2006501207 A5 JP 2006501207A5 JP 2004525343 A JP2004525343 A JP 2004525343A JP 2004525343 A JP2004525343 A JP 2004525343A JP 2006501207 A5 JP2006501207 A5 JP 2006501207A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- crystalline form
- composition
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000000414 obstructive effect Effects 0.000 claims description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 claims 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 claims 1
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960002848 formoterol Drugs 0.000 claims 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 229960002052 salbutamol Drugs 0.000 claims 1
- 229960004017 salmeterol Drugs 0.000 claims 1
- 150000003839 salts Chemical group 0.000 claims 1
- 239000012453 solvate Chemical group 0.000 claims 1
- 229960000195 terbutaline Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0217504.0 | 2002-07-29 | ||
| GBGB0217504.0A GB0217504D0 (en) | 2002-07-29 | 2002-07-29 | Organic compounds |
| PCT/EP2003/008314 WO2004013156A1 (en) | 2002-07-29 | 2003-07-28 | Polymorphis of a known thiophenecarboxylic acid dodecahydrocyclopenta (a) phenanthrenyl ester |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006501207A JP2006501207A (ja) | 2006-01-12 |
| JP2006501207A5 true JP2006501207A5 (enExample) | 2009-05-07 |
Family
ID=9941275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004525343A Pending JP2006501207A (ja) | 2002-07-29 | 2003-07-28 | 有機化合物 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7683048B2 (enExample) |
| EP (2) | EP1554303B1 (enExample) |
| JP (1) | JP2006501207A (enExample) |
| KR (1) | KR100688371B1 (enExample) |
| CN (1) | CN1305892C (enExample) |
| AR (1) | AR040692A1 (enExample) |
| AT (1) | ATE349459T1 (enExample) |
| AU (1) | AU2003251651B2 (enExample) |
| BR (1) | BR0313044A (enExample) |
| CA (1) | CA2493330C (enExample) |
| CY (1) | CY1106406T1 (enExample) |
| DE (1) | DE60310747T2 (enExample) |
| DK (1) | DK1554303T3 (enExample) |
| EC (1) | ECSP055579A (enExample) |
| ES (1) | ES2279970T3 (enExample) |
| GB (1) | GB0217504D0 (enExample) |
| HK (1) | HK1080484B (enExample) |
| IL (2) | IL166287A0 (enExample) |
| MX (1) | MXPA05001173A (enExample) |
| MY (1) | MY136407A (enExample) |
| NO (1) | NO20050806L (enExample) |
| NZ (2) | NZ537868A (enExample) |
| PE (1) | PE20040722A1 (enExample) |
| PL (1) | PL209409B1 (enExample) |
| PT (1) | PT1554303E (enExample) |
| RU (2) | RU2330043C2 (enExample) |
| SI (1) | SI1554303T1 (enExample) |
| TW (1) | TWI309164B (enExample) |
| WO (1) | WO2004013156A1 (enExample) |
| ZA (1) | ZA200500370B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
| SI1305329T2 (sl) | 2000-08-05 | 2015-07-31 | Glaxo Group Limited | S-fluorometil ester 6alfa,9alfa-difluoro-17alfa-(2-furanilkarboksil)oksi-11beta-hidroksi- 16alfa-metil-3-okso-androst-1,4-dien-17-karbotiojske kisline kot protivnetno sredstvo |
| CA2445839A1 (en) | 2001-04-30 | 2002-11-07 | Glaxo Group Limited | Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| GB0523654D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523656D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0603783D0 (en) * | 2006-02-24 | 2006-04-05 | Novartis Ag | Organic compounds |
| MX2010010073A (es) * | 2008-03-14 | 2010-10-04 | Otsuka Pharma Co Ltd | Inhibidor de la metaloproteasa de matriz-2 y/o de la metaloproteasa de matriz-9. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU550939A1 (ru) * | 1975-05-19 | 1994-07-15 | Институт химии древесины АН ЛатвССР | 1,2,3,4,4а,4в,5,6,10,10а -декагидро -6- хлорацетоксиметил -1,4а-диметил -7- (1-метилэтил) -1- фенантренкарбоновая кислота или ее соли |
| JPH08291073A (ja) * | 1995-04-22 | 1996-11-05 | Kissei Pharmaceut Co Ltd | 医薬品組成物及びその製造方法 |
| GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
-
2002
- 2002-07-29 GB GBGB0217504.0A patent/GB0217504D0/en not_active Ceased
-
2003
- 2003-07-25 AR AR20030102680A patent/AR040692A1/es unknown
- 2003-07-25 PE PE2003000741A patent/PE20040722A1/es not_active Application Discontinuation
- 2003-07-28 WO PCT/EP2003/008314 patent/WO2004013156A1/en not_active Ceased
- 2003-07-28 PL PL373140A patent/PL209409B1/pl not_active IP Right Cessation
- 2003-07-28 AT AT03766325T patent/ATE349459T1/de active
- 2003-07-28 HK HK06100247.5A patent/HK1080484B/en not_active IP Right Cessation
- 2003-07-28 EP EP03766325A patent/EP1554303B1/en not_active Expired - Lifetime
- 2003-07-28 MX MXPA05001173A patent/MXPA05001173A/es active IP Right Grant
- 2003-07-28 CN CNB038180596A patent/CN1305892C/zh not_active Expired - Fee Related
- 2003-07-28 CA CA2493330A patent/CA2493330C/en not_active Expired - Fee Related
- 2003-07-28 TW TW092120513A patent/TWI309164B/zh not_active IP Right Cessation
- 2003-07-28 DE DE60310747T patent/DE60310747T2/de not_active Expired - Lifetime
- 2003-07-28 NZ NZ537868A patent/NZ537868A/en unknown
- 2003-07-28 EP EP06005390A patent/EP1676854A1/en not_active Withdrawn
- 2003-07-28 RU RU2005105688/04A patent/RU2330043C2/ru not_active IP Right Cessation
- 2003-07-28 PT PT03766325T patent/PT1554303E/pt unknown
- 2003-07-28 KR KR1020057001581A patent/KR100688371B1/ko not_active Expired - Fee Related
- 2003-07-28 DK DK03766325T patent/DK1554303T3/da active
- 2003-07-28 AU AU2003251651A patent/AU2003251651B2/en not_active Ceased
- 2003-07-28 RU RU2007143025/04A patent/RU2348646C1/ru not_active IP Right Cessation
- 2003-07-28 SI SI200330721T patent/SI1554303T1/sl unknown
- 2003-07-28 NZ NZ549713A patent/NZ549713A/en unknown
- 2003-07-28 US US10/522,358 patent/US7683048B2/en not_active Expired - Fee Related
- 2003-07-28 BR BR0313044-4A patent/BR0313044A/pt not_active IP Right Cessation
- 2003-07-28 ES ES03766325T patent/ES2279970T3/es not_active Expired - Lifetime
- 2003-07-28 MY MYPI20032832A patent/MY136407A/en unknown
- 2003-07-28 JP JP2004525343A patent/JP2006501207A/ja active Pending
-
2005
- 2005-01-13 IL IL16628705A patent/IL166287A0/xx unknown
- 2005-01-14 ZA ZA200500370A patent/ZA200500370B/en unknown
- 2005-01-26 EC EC2005005579A patent/ECSP055579A/es unknown
- 2005-02-15 NO NO20050806A patent/NO20050806L/no unknown
-
2007
- 2007-03-22 CY CY20071100400T patent/CY1106406T1/el unknown
- 2007-07-26 IL IL184848A patent/IL184848A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5466006B2 (ja) | 非常に速い皮膚浸透率を有するアセトアミノフェン及び関連化合物の正荷電水溶性プロドラッグ | |
| TWI692465B (zh) | 酚系ｔｒｐｖ１促效劑之前藥 | |
| JP2002517438A (ja) | 咳の治療のための組成物及び方法 | |
| CA2781436C (en) | Arachidonic acid analogs and methods for analgesic treatment using same | |
| US20150238456A1 (en) | Methods and compositions for administration of oxybutynin | |
| JP2006501207A5 (enExample) | ||
| EP3558380A1 (de) | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen | |
| US6538035B2 (en) | Use of tolterodine to treat asthma | |
| JP2024056733A (ja) | 薬剤を含む共晶溶媒、並びにその製造および使用方法 | |
| JP2005531612A (ja) | ネフォパムの製剤および痛みの治療におけるその使用 | |
| CN103833713A (zh) | 硝克柳胺化合物晶iii型、其制法和其药物组合物与用途 | |
| JP2022508217A (ja) | Ｔａｓｋ－１およびｔａｓｋ－３チャンネル阻害剤を含有する医薬投薬形態の製造方法、ならびに呼吸障害治療におけるその使用 | |
| CN114288289A (zh) | 具有镇痛和/或止痒功能的药物组合物及其应用 | |
| JP2006506402A (ja) | 四級アンモニウム化合物およびその抗ムスカリン薬としての使用 | |
| AU2013368298B2 (en) | Methods and compositions for administration of oxybutynin | |
| CN101663036B (zh) | 4-环丙基甲氧基-n-(3,5-二氯代-1-氧代-4-吡啶-4-基)-5-(甲氧基)吡啶-2-甲酰胺用于治疗颅脑创伤的用途 | |
| CN106163505A (zh) | 可吸入颗粒相关改进 | |
| CN1897952B (zh) | 中性白细胞增多抑制剂 | |
| TW201028155A (en) | New combination of active ingredients containing a non steroidal anti inflammatory drug and a colchicoside derivative | |
| EP3338764A1 (de) | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen | |
| CN101205214B (zh) | 用于抗炎镇痛的苯并咪唑类化合物 | |
| CN116887825A (zh) | 含有格隆铵·水杨酸盐的药物 | |
| RU2021119540A (ru) | Глутарат 3-(1,2,3,6-тетрагидропиридин-2-ил)пиридина или его фармацевтически приемлемый сольват | |
| EP2266948A1 (en) | Salts of tramadol and diflunisal and their crystal form in the treatment of pain | |
| JPH11209302A (ja) | 抗掻痒剤 |